Cargando…

PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

BACKGROUND: Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez Antolín, A., Martínez-Piñeiro, L., Jiménez Romero, M. E., García Ramos, J. B., López Bellido, D., Muñoz del Toro, J., García García-Porrero, A., Gómez Veiga, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796370/ https://www.ncbi.nlm.nih.gov/pubmed/31619215 http://dx.doi.org/10.1186/s12894-019-0527-8

Ejemplares similares

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
por: Puente, Javier, et al.
Publicado: (2019)

Novel agents in the management of castration resistant prostate cancer
por: Chaturvedi, Shruti, et al.
Publicado: (2014)

Development and prevalence of castration-resistant prostate cancer subtypes
por: Vellky, Jordan E., et al.
Publicado: (2020)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Castration promotes the browning of the prostate tumor microenvironment
por: Alvarez-Artime, Alejandro, et al.
Publicado: (2023)

Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
por: Pereira-Veiga, Thais, et al.
Publicado: (2021)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Anatomía humana /
por: García-Porrero, Juan A.
Publicado: (2020)

Anatomía humana /
por: García-Porrero, Juan A.
Publicado: (2005)

Neuroanatomía humana /
por: García-Porrero, Juan A.
Publicado: (2015)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Blanqueamiento de dientes vitales y no vitales /
por: García Vásquez, Magali Janeth
Publicado: (1995)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
por: Chowdhury, Simon, et al.
Publicado: (2020)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy
por: van der Doelen, Maarten J., et al.
Publicado: (2022)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
por: Angulo, J. C., et al.
Publicado: (2022)

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation
por: Vargas Ahumada, Joel, et al.
Publicado: (2022)

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
por: Grasso, Catherine S., et al.
Publicado: (2012)

Prevalence of fatigue during the SARS-CoV-2 pandemic in patients and workers of a hemodialysis unit
por: Hérnandez García, Elena, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

A Case of Castration for Hypertrophied Prostate
Publicado: (1897)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Ischemic Gangrene of the Glans following Penile Prosthesis Implantation
por: García Gómez, Borja, et al.
Publicado: (2013)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Eutanasia y autonomía vital
por: García Peña, Claudia
Publicado: (2013)

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
por: Westin, P., et al.
Publicado: (1995)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis
por: Hu, Xiaoyong, et al.
Publicado: (2015)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3gk97h8p8s0uukhuonllg81j4